evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomat... by Jeffrey L. Cummings, Alireza Atri, Howard H. Feldman, Oskar Hansson, Mary Sano, Filip K. Knop, Peter Johannsen, Teresa León, Philip Scheltens

Get full text

Benchmarking Alzheimer’s disease prediction: personalised risk assessment using polygenic risk scores across various methodologies and genome-wide studies by Eftychia Bellou, Woori Kim, Ganna Leonenko, Feifei Tao, Emily Simmonds, Ying Wu, Niklas Mattsson-Carlgren, Oskar Hansson, Michael W. Nagle, Valentina Escott-Price, the Alzheimer’s Disease Neuroimaging Initiative

Get full text

Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment by Katharina Bolsewig, Eline A. J. Willemse, Pascual Sánchez-Juan, Alberto Rábano, Minerva Martínez, James D. Doecke, Giovanni Bellomo, Lisa Vermunt, Daniel Alcolea, Steffen Halbgebauer, Sjors in ‘t Veld, Niklas Mattsson-Carlgren, Katerina Veverova, Christopher J. Fowler, Lynn Boonkamp, Marleen Koel-Simmelink, Zulaiga Hussainali, Daimy N. Ruiters, Lorenzo Gaetani, Andrea Toja, Juan Fortea, Yolande Pijnenburg, Afina W. Lemstra, Wiesje M. van der Flier, Jakub Hort, Markus Otto, Oskar Hansson, Lucilla Parnetti, Colin L. Masters, Alberto Lleó, Charlotte E. Teunissen, Marta Del Campo Milán

Get full text